Immuron Limited Reports FY25 Financial Results with Increased Revenue

The latest announcement is out from Immuron ( (IMRN) ).

On September 2, 2025, Immuron Limited announced its financial results for the fiscal year ending June 30, 2025. The company reported a 48.6% increase in revenue from ordinary activities, reaching $7.29 million, driven by increased sales of Travelan® in Australia and North America. Despite the revenue growth, the company incurred a net loss of $5.25 million, a reduction from the previous year’s loss of $6.94 million, attributed to reduced research and development expenses. The company’s cash position decreased significantly to $2.83 million from $11.66 million the previous year, partly due to the maturation of a fixed-term deposit.

The most recent analyst rating on (IMRN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Immuron stock, see the IMRN Stock Forecast page.

Spark’s Take on IMRN Stock

According to Spark, TipRanks’ AI Analyst, IMRN is a Neutral.

Immuron’s overall stock score is primarily impacted by its strong revenue growth yet significant challenges in profitability and cash flow, leading to liquidity concerns. The technical analysis presents a neutral outlook with slight downward pressure. The valuation remains unattractive due to a negative P/E ratio and no dividend yield, further weighing down the score.

To see Spark’s full report on IMRN stock, click here.

More about Immuron

Immuron Limited is a biopharmaceutical company based in Australia, primarily focused on the development and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases. The company markets its products, including Travelan®, in the Australian and North American markets.

Average Trading Volume: 240,472

Technical Sentiment Signal: Sell

Current Market Cap: $12.29M

For an in-depth examination of IMRN stock, go to TipRanks’ Overview page.